NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan

NEUROONE MEDICAL TECHNOLOGIES Corp

Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.
Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 1,500,000 and adding 5% annual evergreen increase starting 2027.
Elected Jeffrey Mathiesen and Edward Andrle as Class III directors for three-year terms.
Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending September 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.